Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα Therapy

Journal of Korean Medical Science

Volumn 29, Issue 1, 2014, Pages 38-42

  Suh, Young Sun ^a   Kwok, Seung Ki ^a   Ju, Ji Hyeon ^a   Park, Kyung Su ^a   Park, Sung Hwan ^a   Yoon, Chong Hyeon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Ankylosing; Arthritis; Rheumatoid; Spondylitis; TNF inhibitor; Tuberculosis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ENZYME INHIBITOR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TNFΑ INHIBITOR; TUBERCULIN TEST; TUBERCULOSIS;

ARTHRITIS, RHEUMATOID; SPONDYLITIS, ANKYLOSING; TNFΑ INHIBITOR; TUBERCULOSIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA RELEASE TESTS; MALE; METHOTREXATE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907424151     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.1.38     Document Type: Article

References (25)

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. Inflix-imab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
2. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rog-ers F, Somerville M, Sturrock R, Wordsworth P. BSR guidelines for pre-scribing TNF-alpha blockers in adults with ankylosing spondylitis: re-port of a working party of the British Society for Rheumatology. Rheu-matology (Oxford) 2005; 44: 939-47.
3. Ehlers S. Tumor necrosis factor and its blockade in granulomatous in-fections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41: S199-203.
4. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Ge-borek P, Jacobsson LT, Lindblad S, Lysholm J, et al. Risk and case char-acteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-92.
5. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuber-culosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
6. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008; 58: 947-52.
7. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascu-al-Gómez E, Mola EM, Carreño L, Figueroa M; BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuber-culosis infection in patients treated with tumor necrosis factor antago-nists. Arthritis Rheum 2005; 52: 1766-72.
8. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-84.
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Mo-reland LW, O'Dell J, Winthrop KL, Beukelman T, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
10. Matsumoto T, Tanaka T, Kawase I. Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 2006; 355: 740-1.
11. Kemta Lekpa F, Marini-Portugal A, Lesprit P, Chevalier X, Claudepierre P. Safe re-initiation of infliximab in a patient with renal tuberculosis. Clin Exp Rheumatol 2009; 27: 534.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheuma-tism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
13. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classifica-tion criteria. Rheumatology (Oxford) 2012; 51: vi5-9.
14. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic cri-teria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
15. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, et al. The Assessment of Spon-dyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31.
16. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Re-comm Rep 2010; 59: 1-25.
17. Korean National Tuberculosis Association. Trend of case notification rate per 100,000 by year, 2004-2011. Available at http://www.knta.or.kr [accessed on 1 September 2013].
18. Kim HW, Park JK, Yang JA, Yoon YI, Lee EY, Song YW, Kim HR, Lee EB. Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area. Clin Rheumatol 2013. doi: 10.1007/s10067-013-2387-z.
19. Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, Schwenke R, Burmester GR, Diel R, Feuchtenberger M, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis 2012; 71: 1791-5.
20. Vernon A. Treatment of latent tuberculosis infection. Semin Respir Crit Care Med 2013; 34: 67-86.
21. Van den Broek M, Lems WF, Allaart CF. Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol 2012; 30: S21-6.
22. Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sie-per J, Braun J. Long-term efficacy and safety of etanercept after readmin-istration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005; 44: 342-8.
23. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromni-ca-Ihle E, Kellner H, Schneider M, Sörensen H, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spon-dylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 7: R439-44.
24. Aslanidis S, Pyrpasopoulou A, Douma S, Petidis K. Is it safe to readmin-ister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum 2008; 58: 327-8.
25. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pal-lot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, et al. Risk of tu-berculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biothera-pies registry. Arthritis Rheum 2009; 60: 1884-94.